MARKET

ATRA

ATRA

Atara Biotherape
NASDAQ
4.960
-0.030
-0.60%
After Hours: 4.920 -0.04 -0.81% 18:56 03/25 EDT
OPEN
5.07
PREV CLOSE
4.990
HIGH
5.35
LOW
4.950
VOLUME
66.12K
TURNOVER
--
52 WEEK HIGH
19.15
52 WEEK LOW
3.920
MARKET CAP
40.56M
P/E (TTM)
1.930
1D
5D
1M
3M
1Y
5Y
1D
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Barchart · 18h ago
Securities Fraud Investigation Into Atara Biotherapeutics, Inc. (ATRA) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Barchart · 23h ago
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit
PR Newswire · 1d ago
INVESTOR ALERT: Securities Class Action Filed Against Atara Biotherapeutics, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
Barchart · 1d ago
Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders to Contact the Firm for Information About Their Rights
Barchart · 2d ago
Weekly Report: what happened at ATRA last week (0316-0320)?
Weekly Report · 3d ago
Atara Biotherapeutics files to sell 400K shares of common stock for holders
TipRanks · 03/17 20:20
Atara Biotherapeutics GAAP EPS of $2.61 beats by $4.06, revenue of $120.8M
Seeking Alpha · 03/17 15:48
More
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.

Webull offers Atara Biotherapeutics Inc stock information, including NASDAQ: ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.